3.2.5. Products of Oxidative Modifications

The concentrations of all the evaluated products of oxidative modifications: AGE, AOPP, LOOH and MDA were considerably higher in NWS (↑80%, *p* = 0.00001; ↑232%, *p* = 0.00002; ↑91%, *p* = 0.00001; ↑194%, *p* = 0.00001, respectively), SWS (↑97%, *p* = 0.00001; ↑476%, *p* = 0.00001; ↑46%, *p* = 0.00001; ↑96%, *p* = 0.00001, respectively) and plasma (↑3%, *p* = 0.0007; ↑31%, *p* = 0.0003; ↑77%, *p* = 0.00001; ↑42%, *p* = 0.00001, respectively) of HT patients compared to the values of these parameters obtained in the control group (Figure 3).

3.2.6. Comparison of Antioxidants and Redox Balance Markers between NWS and SWS

Control

We observed significantly higher activity of SOD, CAT, Px (*p* < 0.0001, *p* < 0.0001, *p* < 0.0001, respectively) and GSH, UA, TAC, OSI, AOPP, LOOH and MDA (*p* < 0.0001, *p* < 0.0001, *p* < 0.0001, p < 0.0001, *p* < 0.0001, *p* < 0.0001, *p* < 0.0001, respectively) concentration in SWS vs. NWS of the control women.

**Figure 3.** Oxidative damage in NWS, SWS and plasma of the patients and control group. Data are shown as median (minimum–maximum). AGE—advanced glycation end products; AOPP—advanced oxidation protein products; LOOH—lipid hydroperoxides; MDA—malondialdehyde; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva. \*\*\* *p* < 0.001, and \*\*\*\* *p* < 0.0001.

HT Women

The activity of SOD, CAT, Px (*p* < 0.0001, *p* < 0.0001, *p* < 0.0001, respectively) and GSH, TOS, OSI and MDA (*p* = 0.025, *p* < 0.0001, *p* < 0.0001, *p* < 0.0001, respectively) concentrations were significantly higher in SWS compared to NWS of HT women (Table 3).

3.2.7. Saliva–Blood Ratio
